GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Research & Development

Simcere Pharmaceutical Group (HKSE:02096) Research & Development : HK$1,710 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Simcere Pharmaceutical Group's Research & Development for the six months ended in Dec. 2023 was HK$861 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,710 Mil.


Simcere Pharmaceutical Group Research & Development Historical Data

The historical data trend for Simcere Pharmaceutical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Research & Development Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 797.19 1,353.76 1,734.73 1,930.00 1,709.73

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 967.23 763.73 1,202.42 848.66 861.07

Simcere Pharmaceutical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,710 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simcere Pharmaceutical Group  (HKSE:02096) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Simcere Pharmaceutical Group Research & Development Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines